SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Drug Development
Retinal Tissue Restored in Patients with Dry AMD, Heralding Paradigm Shift
Retinal tissue has been regrown in three patients with age-related macular degeneration with geographic atrophy or dry (atrophic) AMD in a Phase I/IIa study conducted by Lineage Cell Therapeutics.
June 13, 2021
 · 
4 min read
 · 
Gail Dutton
Drug Development
South African HIV Patient Was a Natural Laboratory for SARS-CoV-2 Mutations
An immunocompromised patient in South Africa became a veritable COVID-19 variant laboratory as the virus mutated more than 30 times in 216 days of her infection, according to recent, not-yet-peer-reviewed research paper published in medRxiv.
June 10, 2021
 · 
4 min read
 · 
Gail Dutton
Business
Biotech Whisperer John Edwards Seeks the Extraordinary at Verseau
John Edwards, newly-appointed CEO of Verseau Therapeutics, is continually searching for something special.
June 10, 2021
 · 
5 min read
 · 
Gail Dutton
Courtesy of Michael Vi/Getty Images
Business
Genentech’s Dr. Charles Fuchs: “The Era of Personalized Cancer Care is Here”
BioSpace caught up with Charles Fuchs, M.D., SVP, Global Head of Oncology & Hematology Product Development, Genentech during the ASCO meeting on personalized cancer care.
June 9, 2021
 · 
6 min read
 · 
Gail Dutton
Can H10N3 Avian Flu strain become the next new pan
Drug Development
Will the H10N3 Avian Flu Strain, Now in Humans, Become the Next Pandemic?
The first human case of H10N3 avian flu was diagnosed in China in late May. Chinese health authorities claim a low risk of contagion. Learn more about it here.
June 8, 2021
 · 
3 min read
 · 
Gail Dutton
NBTXR3 helping in strengthening immune system.
Nanobiotix’s Radiotherapy Enhancer NBTXR3 for Tumors Also Primes the Immune System
Nanobiotix is developing a way for its locally-injected radio enhancer NBTXR3 for solid tumors to treat metastasized cancers. Here’s what you need to know about it.
June 4, 2021
 · 
5 min read
 · 
Gail Dutton
Courtesy of Abbvie Inc.
Drug Development
Migraines Be Gone: AbbVie’s Atogepant Reduces Headache Frequency and Severity
Migraine headaches can be reduced in frequency and severity by atogepant, an oral therapy developed by AbbVie. So migraines will be gone sooner than we think.
June 3, 2021
 · 
4 min read
 · 
Gail Dutton
Pharm Country
Iveric Bio Expands into Gene Therapy for Untreated Retinal Diseases
When Iveric Bio established its gene therapy advisory committee recently, the move signaled the opening of a second front in its mission to treat retinal diseases for which there are no treatments.
June 2, 2021
 · 
5 min read
 · 
Gail Dutton
MyMD Pharma Develops Low-Toxicity, Plant-Based TNF-α Regulator
MyMD Pharmaceuticals’ TNF-α regulator may be able to be commercialized without the black-box warnings that accompany so many TNF-α therapies.
June 1, 2021
 · 
4 min read
 · 
Gail Dutton
A great wave of success in diabetic retinopathy.
Policy
ISCGT Meeting Calls for Systemic Ecosystem Innovation Across the Industry
To develop and commercialize them with maximum efficiency, the FDA, scientists and developers must innovate, according to panelists speaking during the Presidential Plenary on Commercialization at the International Society of Cell & Gene Therapy on May 26.
May 28, 2021
 · 
5 min read
 · 
Gail Dutton
Pharm Country
Legend Biotech’s CEO Ying Huang on Cilta-cel’s High PFS in Myeloma Patients
Legend Biotech and its partner Janssen are presenting six abstracts at the ASCO meeting in June detailing ciltacabtagene autoleucel (cilta-cel) CAR-T studies in multiple myeloma.
May 27, 2021
 · 
5 min read
 · 
Gail Dutton
Business
CytoReason and Ferring Pair Up, Using AI to Improve IBD Drug Options
The purpose is to develop cell-based disease models to accelerate drug discovery and reduce development costs.
May 26, 2021
 · 
4 min read
 · 
Gail Dutton
aptaTargets’ First-in-Human Data Shows Efficacy of Aptamers in Stroke
Madrid-based aptaTargets S.L. announced data from its first-in-human trial using its ApTOLL aptamer to protect patients against the deleterious effects of acute ischemic stroke.
May 21, 2021
 · 
4 min read
 · 
Gail Dutton
Drug Development
Annovis Bio Shows Alzheimer’s Reversal in Humans in Phase II Study
Preliminary data from Annovis Bio’s Phase II study of ANVS401 shows significant cognitive improvements in Alzheimer’s patients after only one month of treatment.
May 21, 2021
 · 
4 min read
 · 
Gail Dutton
PolyPeptide Group Outlines Cost-Effective Green Methods for Peptide Synthesis
Recent work by the PolyPeptide Group, a Swiss contract manufacturing organization (CMO), shows that green chemistry is not only feasible, but also is economically sound.
May 19, 2021
 · 
4 min read
 · 
Gail Dutton
Load More